Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 18 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

33%

6 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (3)
P 1 (1)
P 2 (7)
P 3 (6)

Trial Status

Completed7
Recruiting6
Active Not Recruiting3
Unknown1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT07033494Phase 2RecruitingPrimary

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

NCT06709014Phase 3RecruitingPrimary

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

NCT04777396Phase 3CompletedPrimary

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

NCT07496021Not ApplicableRecruitingPrimary

Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease

NCT04777409Phase 3CompletedPrimary

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

NCT07485153Not Yet Recruiting

A Study to Compare Two Different Sleep Tests in Participants With No Symptoms or Early Symptoms of Alzheimer's Disease

NCT04693520Phase 2CompletedPrimary

Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease

NCT07252440Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease

NCT04770220Phase 3CompletedPrimary

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

NCT06304883Phase 3Active Not RecruitingPrimary

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

NCT03887455Phase 3Active Not RecruitingPrimary

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

NCT05531656Phase 2Active Not RecruitingPrimary

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

NCT04599764Not ApplicableRecruiting

High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Early Alzheimer's Disease

NCT05161715Phase 2CompletedPrimary

Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease

NCT06565143Not ApplicableRecruiting

Effect of Transcranial Alternating Current Stimulation(tACS) for Early Alzheimer's Disease

NCT04498650Phase 2CompletedPrimary

A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD

NCT05122598Phase 2Unknown

Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease

NCT02859207Phase 1CompletedPrimary

A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects

Showing all 18 trials

Research Network

Activity Timeline